162 related articles for article (PubMed ID: 20861007)
21. Hepatitis C virus-associated hypobetalipoproteinemia is correlated with plasma viral load, steatosis, and liver fibrosis.
Petit JM; Benichou M; Duvillard L; Jooste V; Bour JB; Minello A; Verges B; Brun JM; Gambert P; Hillon P
Am J Gastroenterol; 2003 May; 98(5):1150-4. PubMed ID: 12809841
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C virus NS3-4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic.
Thomson JA; Perni RB
Curr Opin Drug Discov Devel; 2006 Sep; 9(5):606-17. PubMed ID: 17002221
[TBL] [Abstract][Full Text] [Related]
23. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects.
Bartels DJ; Zhou Y; Zhang EZ; Marcial M; Byrn RA; Pfeiffer T; Tigges AM; Adiwijaya BS; Lin C; Kwong AD; Kieffer TL
J Infect Dis; 2008 Sep; 198(6):800-7. PubMed ID: 18637752
[TBL] [Abstract][Full Text] [Related]
24. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
25. Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
Jiang Y; Andrews SW; Condroski KR; Buckman B; Serebryany V; Wenglowsky S; Kennedy AL; Madduru MR; Wang B; Lyon M; Doherty GA; Woodard BT; Lemieux C; Geck Do M; Zhang H; Ballard J; Vigers G; Brandhuber BJ; Stengel P; Josey JA; Beigelman L; Blatt L; Seiwert SD
J Med Chem; 2014 Mar; 57(5):1753-69. PubMed ID: 23672640
[TBL] [Abstract][Full Text] [Related]
26. Natural prevalence of HCV minority variants that are highly resistant to NS3/4A protease inhibitors.
Franco S; Bellido R; Aparicio E; Cañete N; García-Retortillo M; Solà R; Tural C; Clotet B; Paredes R; Martínez MA
J Viral Hepat; 2011 Oct; 18(10):e578-82. PubMed ID: 21914079
[TBL] [Abstract][Full Text] [Related]
27. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
[No Abstract] [Full Text] [Related]
28. Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy.
Ogawa E; Furusyo N; Murata M; Hayashi T; Shimizu M; Mukae H; Toyoda K; Hotta T; Uchiumi T; Hayashi J
Antiviral Res; 2016 Feb; 126():35-42. PubMed ID: 26692214
[TBL] [Abstract][Full Text] [Related]
29. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
Yang SS; Kao JH
Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
[TBL] [Abstract][Full Text] [Related]
30. Danoprevir: First Global Approval.
Markham A; Keam SJ
Drugs; 2018 Aug; 78(12):1271-1276. PubMed ID: 30117020
[TBL] [Abstract][Full Text] [Related]
31. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).
Lenz O; Vijgen L; Berke JM; Cummings MD; Fevery B; Peeters M; De Smedt G; Moreno C; Picchio G
J Hepatol; 2013 Mar; 58(3):445-51. PubMed ID: 23142061
[TBL] [Abstract][Full Text] [Related]
32. Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.
Schaefer CJ; Kossen K; Lim SR; Lin JH; Pan L; Bradford W; Smith PF; Seiwert SD
Antimicrob Agents Chemother; 2011 Jul; 55(7):3125-32. PubMed ID: 21502634
[TBL] [Abstract][Full Text] [Related]
33. Two years' persistence of naturally present substitution R155K within hepatitis C virus NS3 protease in the absence of protease inhibitor-based therapy.
Colson P; Gérolami R
J Infect Dis; 2011 May; 203(9):1341-2; author reply 1342-3. PubMed ID: 21459820
[No Abstract] [Full Text] [Related]
34. Serum HCV RNA level is not associated with insulin resistance and metabolic syndrome in chronic hepatitis C patients with genotype 1 or 2 infection.
Huang HC; Chuang CS; Hsieh YY; Chang TS; Wei KL; Shen CH; Wu CS; Tung SY
Chang Gung Med J; 2011; 34(5):487-95. PubMed ID: 22035893
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
Hotho DM; de Bruijne J; O'Farrell AM; Boyea T; Li J; Bracken M; Li X; Campbell D; Guler HP; Weegink CJ; Schinkel J; Molenkamp R; van de Wetering de Rooij J; van Vliet A; Janssen HL; de Knegt RJ; Reesink HW
Antivir Ther; 2012; 17(2):365-75. PubMed ID: 22293533
[TBL] [Abstract][Full Text] [Related]
36. The Journey to the Discovery of Boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.
Chen KX; Njoroge FG
Prog Med Chem; 2010; 49():1-36. PubMed ID: 20855037
[No Abstract] [Full Text] [Related]
37. Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy.
Miao M; Jing X; De Clercq E; Li G
Drug Des Devel Ther; 2020; 14():2759-2774. PubMed ID: 32764876
[TBL] [Abstract][Full Text] [Related]
38. Treatment of chronic hepatitis C: anticipated impact of resistance in patients treated with protease inhibitors.
Kronenberger B; Zeuzem S
Curr Gastroenterol Rep; 2009 Feb; 11(1):15-21. PubMed ID: 19166654
[TBL] [Abstract][Full Text] [Related]
39. HCV RNA viral load assessments in the era of direct-acting antivirals.
Cobb B; Pockros PJ; Vilchez RA; Vierling JM
Am J Gastroenterol; 2013 Apr; 108(4):471-5. PubMed ID: 23552304
[TBL] [Abstract][Full Text] [Related]
40. Phase 3 study results released for telaprevir and HCV.
AIDS Patient Care STDS; 2010 Oct; 24(10):685-6. PubMed ID: 20945535
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
